Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MeiraGTx Holdings plc (Nasdaq: MGTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage genetic medicines company with programs in ophthalmology, Parkinson’s disease and radiation-induced xerostomia, MeiraGTx uses SEC reports to communicate material events, financial results and key collaboration agreements to investors.
Among the filings available are current reports on Form 8-K, which MeiraGTx has used to announce quarterly financial and operational results, strategic collaborations and regulatory milestones. For example, the company has filed 8-Ks describing its strategic collaboration and license agreement with Eli Lilly and Company in ophthalmology, its broad collaboration with Hologen Limited to form Hologen Neuro AI Ltd, and the receipt of foreign direct investment clearances related to that collaboration. Other 8-Ks reference the release of financial results for specific quarters.
In addition to current reports, investors can use this page to locate MeiraGTx’s periodic filings, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, when available. These documents typically contain detailed discussions of the company’s clinical pipeline, including programs like AAV-AIPL1, AAV2-hAQP1 and AAV-GAD, as well as risk factors, management’s discussion and analysis, and information on its manufacturing infrastructure and collaborations.
Stock Titan enhances access to these filings by providing real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the key points in plain language. Users can quickly see which filings relate to clinical data, regulatory designations, strategic partnerships or financing. The filings page also surfaces information on items such as material definitive agreements, like the collaboration and license agreement with Eli Lilly, and other disclosures that may affect MeiraGTx’s development plans and capital position.
For those tracking MeiraGTx’s progress in genetic medicine, this page offers a structured view of how the company reports its activities to regulators and the market, from clinical and regulatory milestones to manufacturing and partnership developments.
MeiraGTx Holdings plc’s Chief Medical Officer, Robert K. Zeldin, reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, resulting in 35,000 restricted share units converting into the same number of ordinary shares at an exercise price of $0.
To cover taxes due on this vesting, 13,951 ordinary shares were automatically withheld and disposed of at a price of $7.42 per share. After these transactions, Zeldin directly beneficially owned 168,340 ordinary shares of MeiraGTx. The filing indicates these are routine equity award vesting and tax-withholding events rather than open-market purchases or discretionary sales.
MeiraGTx Holdings plc reported an insider equity transaction for its General Counsel and Secretary, Robert J. Wollin. On January 17, 2026, one-half of a prior award of restricted share units vested, resulting in 50,000 ordinary shares being issued upon conversion of the vested units at an exercise price of $0 per share. In a related transaction, 27,206 ordinary shares were withheld at $7.42 per share to cover taxes due on the vesting. Following these transactions, Wollin directly owned 52,076 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc Chief Development Officer Stuart Naylor reported equity compensation activity on January 17, 2026. One-half of a prior grant of restricted share units vested, converting 75,000 restricted share units into 75,000 ordinary shares at an exercise price of $0. To cover taxes due upon vesting, 35,250 ordinary shares were withheld at a value of $7.42 per share. After these transactions, Naylor directly owned 682,916 ordinary shares of MeiraGTx and continued to hold 75,000 restricted share units that remain outstanding.
MeiraGTx Holdings plc officer reports RSU vesting and related share withholding. On January 17, 2026, CFO & COO Richard Giroux had 310,000 restricted share units vest, each converting into one ordinary share at an exercise price of $0. In a separate transaction the same day, 163,916 ordinary shares were disposed of at $7.42 per share to cover taxes due upon vesting. Following these transactions, Giroux directly beneficially owned 999,256 ordinary shares, with additional indirect holdings of 5,152 shares through a spouse and 85,000 shares through Aigle Healthcare Partners III LLC.
MeiraGTx Holdings plc insider Alexandria Forbes, the President and CEO, reported equity award vesting and related tax withholding. On January 17, 2026, 310,000 restricted share units vested from a grant originally made on January 17, 2024, with each unit converting into one ordinary share upon vesting.
To cover taxes on this vesting, 163,916 ordinary shares were withheld at a price of $7.42 per share. After these transactions, Forbes directly holds 1,482,243 ordinary shares of MeiraGTx and 310,000 restricted share units as derivative securities.
MeiraGTx Holdings plc Chief Medical Officer Robert K. Zeldin filed a Form 4 showing routine equity compensation activity. On January 7, 2026, 17,500 restricted share units granted on January 7, 2022 vested, with each unit converting into one ordinary share. To cover taxes on this vesting, 6,729 ordinary shares were withheld at a price of $7.73 per share rather than being sold in the open market.
After these transactions, Zeldin directly beneficially owned 147,291 ordinary shares of MeiraGTx. The filing reflects compensation-related vesting and associated tax withholding rather than discretionary market buying or selling.
MeiraGTx Holdings plc’s general counsel and secretary, Robert J. Wollin, reported routine equity award activity involving the company’s ordinary shares. On January 7, 2026, one quarter of his restricted share units granted on January 7, 2022 vested, converting 7,500 restricted share units into 7,500 ordinary shares at an exercise price of $0. In connection with this vesting, 4,364 ordinary shares were withheld at a price of $7.73 per share to cover tax obligations. After these transactions, he directly beneficially owned 29,282 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc’s Chief Development Officer Stuart Naylor reported routine equity award activity involving restricted share units and ordinary shares. On January 7, 2026, 37,500 restricted share units vested and converted into the same number of ordinary shares, reflecting one-quarter of an award granted on January 7, 2022. Each restricted share unit converts into one ordinary share upon vesting. To cover tax withholding on this vesting, 17,625 ordinary shares were withheld at a price of $7.73 per share. After these transactions, Naylor directly held 643,166 ordinary shares of MeiraGTx Holdings plc.
MeiraGTx Holdings plc CFO & COO Richard Giroux reported equity compensation activity involving the company’s ordinary shares. On January 7, 2026, 52,500 restricted share units vested, with each unit converting into one ordinary share. As part of the vesting, 28,822 ordinary shares were withheld at a price of $7.73 per share to cover taxes on the award. Following these transactions, Giroux directly beneficially owned 853,172 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc President & CEO and director Alexandria Forbes reported equity award activity in a Form 4. On January 7, 2026, one-quarter of a prior grant of restricted share units vested, converting 62,500 restricted share units granted on January 7, 2022 into the same number of ordinary shares on a one-for-one basis. To cover tax obligations on this vesting, 34,074 ordinary shares were withheld at a price of $7.73 per share. Following these transactions, Forbes directly beneficially owns 1,336,159 ordinary shares of MeiraGTx.